1. Parkinson's disease 2. Parkinson´s pharmacological therapy 3. Dopamine synthesis 4. Dopamine storage and release 5. Dopamine oxidative deamination 6. Dopamine methylation 7. Dopamine oxidation to neuromelanin and neurotoxic metabolites 8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity 9. Preclinical model based on exogenous neurotoxins for Parkinson's disease 10. Preclinical models based on genetic mutations associated with the familial form of Parkinson´s disease 11. Preclinical models based on endogenous neurotoxins 12. Conclusions
Dr. Juan Segura-Aguilar, PhD, is a professor of molecular and clinical pharmacology at the University of Chile, Santiago, Chile. He obtained his PhD in biochemistry from Stockholm University, Stockholm, Sweden in 1989. He was previously an associate professor at Uppsala University, Uppsala, Sweden. In 1998, he began as an associate professor at University of Chile, and since 2001 has been a full professor. His research has been focused on mechanisms involved in dopaminergic neuron degeneration in Parkinson´s disease. He has more than 140 publications of his research work on neurodegenerative disorders.